IL-8 could indicate resistance to GSK's pazopanib; HTG developing biomarker for Sanofi diagnostic;

> Interleukin-8 may be an indicator of tumor resistance and poor survival in urothelial cancer patients treated with GlaxoSmithKline's ($GSK) Phase II drug pazopanib. Press release

> Using its qNPA technology, HTG Molecular Diagnostics is collaborating with Sanofi ($SNY) to identify biomarkers for a companion diagnostic to determine those patients who will most likely to respond to an investigational agent from the drugmaker. HTG release

> Another Alzheimer's disease blood test is in development at Newcastle University that could have potential in early-stage disease. Item

> In patients with BRAF-mutated metastatic melanoma, a second mutation in MEK1 doesn't add to resistance to BRAF inhibitor drugs. Press release

> Protein Aurora-A has been linked with a number of cancers, and data presented at AACR have hooked it up with head and neck cancer, too. Release

> Bone biomarker study finds tenofovir could affect the skeleton in HIV/AIDS patients. Article

> A Metamark Genetics' prostate cancer test has completed proof of principle studies, which replicate the results of a previous positive study. Metamark release

> Israel's Micromedic Technologies has bought a third of biomarker-based cancer diagnostics company BioMarCare Technologies, with an option to gain an extra 20%. Report

> Spinal Muscular Atrophy Foundation has launched a biomarker assay panel to evaluate the severity of the disease and its progression. SMA Foundation release

> GE Healthcare ($GE) has licensed peptides binding to c-Met as diagnostics and as patient selection biomarkers in oncology; the peptides may also have uses in imaging. GE release

> Medical student gets grant to seek biomarkers for broken heart syndrome. News

> An early PET response could predict survival in patients with soft tissue sarcomas. Press release

> Legumain could be a biomarker for diagnosis and prognosis of human ovarian cancer. Abstract

> The National Cancer Institute is looking for partners to co-develop biomarkers for liver cancer. Opportunity

And Finally… Tiny starfruit-shaped gold particles could help find biomarkers. Article

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.